Edgewise Q3 net loss $34.1M; Phase 2 CANYON data on track for Dec 2024

Edgewise Therapeutics, Inc.

2024-Q3 EPS reported -$1.03

Net loss $34.1M ($0.36 per share) vs $31.5M ($0.34) prior quarter; cash $492.5M.
R&D expenses $32.2M (up $1.5M QoQ); G&A $8.2M (up $0.8M QoQ).
Top-line CANYON (Becker) data expected December 2024; EDG-7500 28-day data Q1 2025.
CIRRUS-HCM single dose: 67% mean reduction in resting LVOT gradient; no meaningful LVEF change.
LYNX (Duchenne) data due Q4 2024; FOX trial over-enrolled within two months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.